Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Need to clarify & very clear

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Mar 05, 2024 7:50pm

107 Views

Post# 35916966

RE:Need to clarify & very clear

It's been a year and a half since the "stellar" prelinary P2 panc results were announced.

MC has failed to close a deal with BP (partnership or buyout) despite having more than enough time.

He has failed. What's more will he bring to the table in the next few weeks or months?

The CC on Thursday will be very revealing. More BS or some real substance from ONC?

<< Previous

Bullboard Posts

Next >>

Who is cashing in on fintech’s untapped potential?